Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5636_Библиотеки_им_академика_М_И_Перельмана
.pdf
221
9 Advances in Biodegradable Ocular Drug Delivery Systems
https://t.me/med1917
dexamethasone-PCL implant designed for long-term drug release (Fialho et al.
2008). The implant provides controlled and prolonged delivery of dexamethasone
in vitro, releasing 25% of its total drug load in 21 weeks, and loses mass slowly, as
confirmed by scanning electron microscopy. The implants showed good short-term
ocular tolerability in rabbits.
A biodegradable, intravitreal 2-mg cyclosporine A drug delivery system formulated with PGLC has been investigated in an experimental model of chronic
uveitis in rabbits (Dong et al. 2006a). The efficacy of the implant was compared
with that of orally administered cyclosporine A (15 mg/kg daily), no treatment,
and treatment with a nonmedicated implant. At all timepoints in the 14-week
study, inflammation was significantly lower in rabbits with experimentally
induced uveitis that received the cyclosporine-PGLC drug delivery system as
compared with those that received vehicle, sham implant, or oral cyclosporine.
Rabbits treated with the cyclosporine-PGLC drug delivery system also showed
significantly less electroretinographic b-wave depression. Mean intravitreal
cyclosporine levels in rabbits implanted with the cyclosporine-PGLC drug
delivery system were 102.2–145.5
491.0–575.2 ng/mL at 4–10 weeks, and 257.3 ng/mL at 14 weeks. No toxicity
associated with the implant was detected. A biodegradable tacrolimus-PGLC
drug delivery system designed for anterior chamber implantation has been
investigated for the prolongation of corneal allograft survival in a rabbit model
of high-risk keratoplasty (Shi et al. 2005). The implant, which contains a total
of 0.5 mg of FK506, produced peak aqueous humor drug concentrations
(17.9 ± 2.3 ng/mL) after 28 days, and drug release was sustained for at least 168
days. The implant significantly prolonged graft survival time and produced no
adverse reactions.
ng/mL at 1–3 weeks postimplantation,
9.6.5 Poly(Ortho Ester)-Based Implants
Several preliminary studies have reported the use of POE as a delivery vehicle for
5-fluorouracil (Einmahl et al. 1999, 2001; Bernatchez et al. 1994). Einmahl and
colleagues investigated an injectable, sustained-release POE-based 5-fluorouracil
ointment in an experimental glaucoma filtration model in rabbits. The ointment
significantly decreased intraocular pressure and led to persistence of the filtering
bleb at days 9–28 after trabeculectomy (Einmahl et al. 2001). Corneal toxicity with
the POE ointment was significantly lower as compared with conventional 5-fluorouracil tamponade. Histopathologic analysis indicated that POE was well tolerated and did not lead to fibrosis. The same research group also developed a
POE-based ointment capable of delivering dexamethasone and 5-fluorouracil concomitantly for the potential treatment of intraocular proliferative disorders (Einmahl
et al. 1999). A POE-based 5-chlorouracil drug delivery system has also been devel-
oped and its performance was evaluated in a glaucoma filtration surgery model in
rabbits (Polak et al. 2008).

222
S.S. Lee et al.
https://t.me/med1917
9.6.6 Polyanhydride-Based Implants
Jampel and associates developed biodegradable subscleral PAH-based discs
(a copolymer of 25:75 1,3-bis[p-carboxyphenoxy] propane and sebacic acid) for the
delivery of various antiproliferative agents and evaluated their effects in vitro and in
a primate glaucoma filtration surgery model (Jampel et al. 1990, 1991, 1993; Uppal
et al. 1994). PAH discs impregnated with 5-fluorouridine inhibited fibroblast proliferation in vitro, provided sustained drug delivery for at least 16 days in vivo, and
prolonged the duration of intraocular pressure reduction following filtration surgery
(Jampel et al. 1990). PAH discs were also developed to provide sustained delivery
of the antiproliferative agents taxol and etoposide (VP-16) (Jampel et al. 1991).
In vitro, the discs delivered taxol for 100 days and at concentrations exceeding
taxol’s ID50 threefold for fibroblast proliferation (3 ng/mL). PAH discs with etoposide
provided sustained release for 31 days (Jampel et al. 1991). PAH discs impregnated
with taxol (50 mg) or etoposide (1 mg) have been investigated as an adjunct to
filtration surgery in monkeys (Jampel et al. 1993). PAH disks containing taxol, but
not etoposide, had a marked beneficial effect on intraocular pressure and bleb
appearance postsurgically. Etoposide-PAH discs (1 mg) placed subconjunctivally in
healthy rabbit eyes provided a nearly linear rate (30 mg/day) of drug release over
12 days, except for a burst occurring between days 6 and 7. Steady-state drug levels
were 89 ng/mg in the conjunctiva and sclera, 195 ng/mL in the vitreous, and
29 ng/mL in serum; these levels were deemed sufficient to reduce fibroblast proliferation after glaucoma surgery (Uppal et al. 1994).
9.6.7 Other Biodegradable Polymer-Based Implants
Felt-Baeyens and colleagues have developed a scleral implant consisting of a compression-molded matrix of triamcinolone acetonide and high molecular weight
(100,000–150,000) PMM (PMM2.1.2), a novel synthetic polymer, with ethoxylated
derivatives of stearic acid (Simulsol) or oligomers of methylidene malonate as plasticizers (Felt-Baeyens et al. 2006). In rabbits implanted with the triamcinolonePMM devices, significant concentrations of triamcinolone acetonide were achieved
in the vitreous and sclera over a 5-week period. Assessments of inflammatory cell
counts and protein leakage into the aqueous humor indicated that the implants were
well tolerated and did not provoke abnormal inflammation.
Hacker and associates have recently developed and evaluated scleral and vitreal
implants consisting of a photocrosslinked poly(propylene fumarate) (PPF)/poly
(N-vinyl pyrrolidone) (PVP) matrix for the delivery of the ophthalmic drugs acetazolamide, dichlorphenamide, and timolol maleate (Hacker et al. 2009). Drug release
rates of up to 4 mg/day were achieved, and the in vitro release of acetazolamide,
dichlorphenamide, and timolol maleate was sustained for approximately 210, 270,
and 250 days, respectively. The implants exhibited a small initial burst release

223
9 Advances in Biodegradable Ocular Drug Delivery Systems
https://t.me/med1917
(<10%) with a subsequent dual mode of drug release controlled by diffusion and
bulk erosion. Drug-free PPF/PVP matrices, when implanted in rabbits for 2 weeks,
showed good ocular biocompatibility. Overall, these preliminary results suggest
that PPF/PVP matrices may be useful for long-term delivery of a variety of ophthalmic drugs.
The efficacy and safety of a biodegradable, scleral cyclosporine-PVA matrix reservoir implant has been investigated for the treatment of recurrent uveitis in horses
(Gilger et al. 2006). Horses with equine recurrent uveitis received episcleral or
deep-scleral lamellar cyclosporine-PVA implants and were monitored for up to 3 years.
Scleral penetration of cyclosporine in
the cyclosporine-PVA implant failed to control inflammatory uveitic episodes.
In contrast, cyclosporine-PVA implants placed in the deep sclera adjacent to the
suprachoroidal space significantly decreased uveitic flare-ups and resulted in therapeutic levels of cyclosporine in most ocular tissues.
vitro was poor, and when placed episclerally,
9.6.8 Drug Delivery Using Polymeric Particles, Gels,
and Contact Lenses
Additional strategies for ocular drug delivery that have been investigated in preclinical studies include biodegradable injectable polymeric particulates (micro/
nano particles, spheres), drug-polymer gels, and drug-eluting polymer-based
contact lenses.
Microsomes are spherical liposomal structures, roughly 0.01–10 mm in diameter,
which consist of vesicular lipid bilayers separated by water or an aqueous buffer
compartment (Conway 2008; Ghate and Edelhauser 2006, 2008). Microsomes can
circumvent cell membrane barriers and protect drugs from metabolic or immune
attack, thereby maximizing drug efficacy while minimizing toxicity. Microspheres
composed of PLGA, PLA, and other biodegradable polymers have been developed
for the sustained ocular delivery of therapeutic drugs (Moritera et
et al. 1995; Wada et al. 1992) such as progesterone (Beck et al. 1979), adriamycin
(Moritera et al. 1992), and Pegaptanib (Carrasquillo et al. 2003). Microspheres
composed of chitosan, a natural biodegradable biopolymer, have been used for the
transcorneal delivery of acyclovir in rabbits (Genta et al. 1997) and to enhance
the ocular delivery of ofloxacin from erodible inserts made from polyethylene oxide
(Di Colo et al. 2002).
Smaller sized particulate drug delivery systems include nanoparticles, nanospheres, and nanocapsules. Nanoparticles are polymeric colloidal particles, ranging
in size from 10 to 1,000 nm, consisting of macromolecular materials for drug
dissolution, entrapment, encapsulation, adsorption, or attachment. Nanospheres are
solid spheres containing drug bound in a matrix or adsorbed on the surface of a
colloidal carrier. Nanocapsules are small capsules with a central cavity surrounded
by a polymeric membrane (Conway 2008; Ghate and Edelhauser 2006, 2008).
al. 1991; Giordano

224
S.S. Lee et al.
https://t.me/med1917
Biodegradable PLA nanoparticles (140 nm) administered intravitreally have been
shown to localize in the retinal pigment epithelium (Bourges et al. 2003), and coating
nanoparticles with PEG has been reported to enhance the therapeutic efficacy of treatment for ocular diseases such as autoimmune uveoretinitis (De Kozak et al. 2004).
Studies on nonbiodegradable drug-impregnated contact lenses for the sustained
release of ocular drugs have been reported by several investigators (Alvarez-Lorenzo
et al. 2006; Schultz et al. 2009; Xinming et al. 2007). Soft contact lenses composed
of nonbiodegradable hydrogels of poly(2-hydroxyethylmethacrylate) (PHEMA) or
hydroxyethylmethacrylate (HEMA) copolymerized with other monomers such as
methacrylic acid, acetone acrylamide, and vinyl pyrrolidone are typically used for
drug impregnation. The amount of drug that can be loaded into contact lenses is
generally low, and drug release is usually rapid and poorly controlled. Entrapping
the drug in a biodegradable nanoparticle prior to incorporation into the contact lens
may be useful for sustaining drug release (Conway 2008).
9.7 Conclusions
Biodegradable polymer-based drug delivery systems display a variety of characteristics that make them ideally suited for the treatment of ocular diseases. Biodegradable
drug delivery systems represent a promising solution to many of the limitations of
conventional techniques for ocular drug delivery, particularly in the treatment of sightthreatening retinal diseases. Several of the polymers used in current biodegradable
drug delivery systems have been demonstrated to be biocompatible and to have an
acceptable ocular safety profile. Additional polymers at the experimental stage of
development are being explored for use in biodegradable drug delivery systems and
are being evaluated in preclinical and preliminary clinical studies. Biodegradable
polymers are versatile in that they can be used to construct delivery systems with
customized release profiles to optimize drug delivery for the treatment of various
diseases of the posterior and anterior segments of the eye. In addition to being useful
for the delivery of novel therapeutic agents, biodegradable drug delivery systems are
being explored as a means for delivering already-established drugs that are not sufficiently effective when administered by conventional routes of administration. Ongoing
clinical research is being conducted to determine the efficacy and safety of biodegradable drug delivery systems in a variety of ocular diseases, and promising new additions to the therapeutic armamentarium can be expected in the future.
References
Alvarez-Lorenzo C, Hiratani H, Concheiro A (2006) Contact lenses for drug delivery: achieving
sustained release with novel systems. Am J Drug Deliv 4(3):131–151
Anon (1971) The dexon polyglycolic acid suture. Med Lett Drugs Ther 13(19):79

225
9 Advances in Biodegradable Ocular Drug Delivery Systems
https://t.me/med1917
Athanasiou KA, Niederauer GG, Agrawal CM (1996) Sterilization, toxicity, biocompatibility and
clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials 17(2):93–102
Athanasiou KA, Agrawal CM, Barber FA, Burkhart SS (1998) Orthopaedic applications for PLA-
PGA biodegradable polymers. Arthroscopy 14(7):726–737
Aukunuru JV, Sunkara G, Ayalasomayajula SP, DeRuiter J, Clark RC, Kompella UB (2002) A
biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase
inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic com-
plications. Pharm Res 19(3):278–285
Avgoustakis K (2008) Polylactic-co-glycolic acid (PLGA). In: Wnek GE, Bowlin GL (eds)
Encyclopedia of biomaterials and biomedical engineering. Informa Healthcare USA, New
York, pp 2259–2269
Bates ER (2008) Primary percutaneous coronary intervention with drug-eluting stents: another
chapter in the stent controversy. Circ Cardiovasc Interv 1(2):87–89
Beck LR, Cowsar DR, Lewis DH, Cosgrove RJ Jr, Riddle CT, Lowry SR, Epperly T (1979) A new
long-acting injectable microcapsule system for the administration of progesterone. Fertil Steril
31:545–551
Beeley NR, Rossi JV, Mello-Filho PA, Mahmoud MI, Fujii GY, de Juan E, Jr VSE (2005)
Fabrication, implantation, elution, and retrieval of a steroid-loaded polycaprolactone subretinal
implant. J Biomed Mater Res A 73(4):437–444
Berinstein DM (2003) New Approaches in the management of diabetic macular edema. Tech
Ophthalmol 1:106–113
Bernatchez SB, Merkli A, Le Minh T, Tabatabay C, Anderson JM, Gurny R (1994) Biocompatibility
racil. J Biomed Mater Res 28:1037–1046
Bourges J-L, Gautier SE, Delie F, Bejjani RA, Jeanny JC, Gurny R, BenEzra D, Behar-Cohen FF
(2003) Ocular drug delivery targeting the retina and retinal pigment epithelium using polylac-
tide nanoparticles. Invest Ophthal Vis Sci 44:3562–3569
Bowland ED, Wnek GE, Bowlin GL (2008) Poly(glycolic acid). In: Wnek GE, Bowlin GL (eds)
Encyclopedia of biomaterials and biomedical engineering. Informa Healthcare USA, New
York, pp 2241–2248
Carrasquillo KG, Ricker JA, Rigas IK, Miller JW, Gragoudas ES, Adamis AP (2003) Controlled
delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres.
Invest Ophthalmol Vis Sci 44:290–299
Chang D, Garcia I, Hunkeler J, Minas T (1999) Phase II results of an intraocular steroid delivery
system for cataract surgery. Ophthalmology 106:1172–1177
Chien YW (1992) Novel drug delivery systems, 2nd edn. Marcel Dekker, New York
Chu CC (2008) Biodegradable polymers: an overview. In: Wnek GE, Bowlin GL (eds) Encyclopedia
of biomaterials and biomedical engineering. Informa Healthcare USA, New York, pp 195–206
Conway BR (2008) Recent patents on ocular drug delivery systems. Recent Pat Drug Deliv Formul
2(1):1–8
da Silva GR, da Silva CA, Jr AE, Oréfice RL (2009) Effect of the macromolecular architecture of
biodegradable polyurethanes on the controlled delivery of ocular drugs. J Mater Sci Mater Med
20(2):481–487
Dafer RM, Schneck M, Friberg TR, Jay WM (2007) Intravitreal ranibizumab and bevacizumab:
a review of risk. Semin Ophthalmol 22(3):201–204
Davis JL, Gilger BC, Robinson MR (2004) Novel approaches to ocular drug delivery. Curr Opin
Mol Ther 6(2):195–205
de Kozak Y, Andrieux K, Villarroya H, Klein C, Thillaye-Goldenberg B, Naud MC, Garcia E,
Couvreur P (2004) Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of
experimental autoimmune uveoretinitis. Eur J Immunol 34:3702–3712
Di Colo G, Zambito Y, Burgalassi S, Serafini A, Saettone MF (2002) Effect of chitosan on in
release and ocular delivery of ofloxacin from erodible inserts based on poly(ethylene oxide).
Int J Pharm 248(1–2):115–122
vitro

226
S.S. Lee et al.
https://t.me/med1917
Doddi N, Versfelt CC, Wasserman D (1977) Synthetic absorbable surgical devices of poly-
dioxanone. US Pat. 4,052,988
Dong X, Shi W, Yuan G, Xie L, Wang S, Lin P (2006a) Intravitreal implantation of the biodegrad-
able cyclosporin A drug delivery system for experimental chronic uveitis. Graefes Arch Clin
Exp Ophthalmol 244(4):492–497
Dong X, Chen N, Xie L, Wang S (2006b) Prevention of experimental proliferative vitreoretinopa-
thy with a biodegradable intravitreal drug delivery system of all-trans retinoic acid. Retina
26(2):210–213
Einmahl S, Zignani M, Varesio E, Heller J, Veuthey JL, Tabatabay C, Gurny R (1999) Concomitant
and controlled release of dexamethasone and 5-fluorouracil from poly(ortho ester). Int J Pharm
185(2):189–198
Einmahl S, Behar-Cohen F, D’Hermies F, Rudaz S, Tabatabay C, Renard G, Gurny R (2001) A
new poly(ortho ester)-based drug delivery system as an adjunct treatment in filtering surgery.
Invest Ophthalmol Vis Sci 42(3):695–700
Emerich DF, Thanos CG (2008) NT-501: an ophthalmic implant of polymer-encapsulated ciliary
neurotrophic factor-producing cells. Curr Opin Mol Ther 10(5):506–515
Eperon S, Bossy-Nobs L, Petropoulos IK, Gurny R, Guex-Crosier Y (2008) A biodegradable
drug delivery system for the treatment of postoperative inflammation. Int J Pharm
352(1–2):240–247
Felt-Baeyens O, Eperon S, Mora P, Limal D, Sagodira S, Breton P, Simonazzi B, Bossy-Nobs L,
Guex-Crosier Y, Gurny R (2006) Biodegradable scleral implants as new triamcinolone
acetonide delivery systems. Int J Pharm 322(1–2):6–12
Fialho SL, Rêgo MB, Siqueira RC, Jorge R, Haddad A, Rodrigues AL, Maia-Filho A, Silva-Cunha
A (2006) Safety and pharmacokinetics of an intravitreal biodegradable implant of dexametha-
sone acetate in rabbit eyes. Curr Eye Res 31(6):525–534
Fialho SL, Behar-Cohen F, Silva-Cunha A (2008) Dexamethasone-loaded poly(epsilon-caprolac-
tone) intravitreal implants: a pilot study. Eur J Pharm Biopharm 68(3):637–646
Frick KD, Foster A (2003) The magnitude and cost of global blindness: an increasing problem that
can be alleviated. Am J Ophthalmol 135(4):471–476
Gaudana R, Jwala J, Boddu SH, Mitra AK (2009) Recent perspectives in ocular drug delivery.
Pharm Res 26(5):1197–1216
Genta I, Conti B, Perugini P, Pavanetto F, Spadaro A, Puglisi G (1997) Bioadhesive microspheres
for ophthalmic administration of acyclovir. J Pharm Pharmacol 49(8):737–742
Ghate D, Edelhauser HF (2006) Ocular drug delivery. Expert Opin Drug Deliv 3(2):275–287
Ghate D, Edelhauser HF (2008) Barriers to glaucoma drug delivery. J Glaucoma 17(2):147–156
Gilger BC, Salmon JH, Wilkie DA, Cruysberg LP, Kim J, Hayat M, Kim H, Kim S, Yuan P, Lee
SS, Harrington SM, Murray PR, Edelhauser HF, Csaky KG, Robinson MR (2006) A novel
bioerodible deep scleral lamellar cyclosporine implant for uveitis. Invest Ophthalmol Vis Sci
47(6):2596–2605
Giordano GG, Chevez-Barrios P, Refojo MF, Garcia CA (1995) Biodegradation and tissue reaction
to intravitreous biodegradable poly(D, L-lactic-co-glycolic)acid microspheres. Curr Eye Res
9:761–768
Gorle AP, Gattani SG (2009) Design and evaluation of polymeric ocular drug delivery system.
Chem Pharm Bull (Tokyo) 57(9):914–919
Guelcher SA (2008) Biodegradable polyurethanes: synthesis and applications in regenerative med-
icine. Tissue Eng B Rev 14(1):3–17
Hacker MC, Haesslein A, Ueda H, Foster WJ, Garcia CA, Ammon DM, Borazjani RN, Kunzler
JF, Salamone JC, Mikos AG (2009) Biodegradable fumarate-based drug-delivery systems for
ophthalmic applications. J Biomed Mater Res A 88(4):976–989
Haller JA, Dugel P, Weinberg DV, Chou C, Whitcup SM (2009) Evaluation of the safety and per-
formance of an applicator for a novel intravitreal dexamethasone drug delivery system for the
treatment of macular edema. Retina 29(1):46–51
Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon
YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group (2010)

227
9 Advances in Biodegradable Ocular Drug Delivery Systems
https://t.me/med1917
Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular
edema due to retinal vein occlusion. Ophthalmology. 117(6):1134–1146
Heller J, Barr J, Ng SY, Abdellauoi KS, Gurny R (2002) Poly(ortho esters): synthesis, character-
ization, properties and uses. Adv Drug Deliv Rev 54(7):1015–1039
Hu M, Huang G, Karasina F, Wong VG (2008) Verisome™, a novel injectable, sustained release,
biodegradable, intraocular drug delivery system and triamcinolone acetonide. Invest Ophthalmol
Vis Sci 49:E-Abstract 5627
Huhtala A, Pohjonen T, Salminen L, Salminen A, Kaarniranta K, Uusitalo H (2008) In vitro bio-
compatibility of degradable biopolymers in cell line cultures from various ocular tissues:
extraction studies. J Mater Sci Mater Med 19(2):645–649
Hutmacher DW, Schantz JT, Lam CX, Tan KC, Lim TC (2007) State of the art and future direc-
tions of scaffold-based bone engineering from a biomaterials perspective. J Tissue Eng Regen
Med 1(4):245–260
Jager RD, Aiello LP, Patel SC, Cunningham ET Jr (2004) Risks of intravitreous injection: a com-
prehensive review. Retina 24(5):676–698
Jain RA (2000) The manufacturing techniques of various drug loaded biodegradable poly(lactide-
co-glycolide) (PLGA) devices. Biomaterials 21(23):2475–2490
Jain R, Shah NH, Malick AW, Rhodes CT (1998) Controlled drug delivery by biodegradable
poly(ester) devices: different preparative approaches. Drug Dev Ind Pharm 24(8):703–727
Jampel HD, Leong KW, Dunkelburger GR, Quigley HA (1990) Glaucoma filtration surgery in
monkeys using 5-fluorouridine in polyanhydride disks. Arch Ophthalmol 108(3):430–435
Jampel HD, Koya P, Leong K, Quigley HA (1991) In vitro release of hydrophobic drugs from
polyanhydride disks. Ophthalmic Surg 22(11):676–680
Jampel HD, Thibault D, Leong KW, Uppal P, Quigley HA (1993) Glaucoma filtration surgery in
nonhuman primates using taxol and etoposide in polyanhydride carriers. Invest Ophthalmol Vis
Sci 34(11):3076–3083
Jiang C, Moore MJ, Zhang X, Klassen H, Langer R, Young M (2007) Intravitreal injections of
GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma.
Mol Vis 13:1783–1792
Kagaya F, Usui T, Kamiya K, Ishii Y, Tanaka S, Amano S, Oshika T (2002) Intraocular dexame-
thasone delivery system for corneal transplantation in an animal model. Cornea 21(2):
200–202
Kane FE, Burdan J, Cutino A, Green KE (2008) Iluvien: a new sustained delivery technology for
posterior eye disease. Expert Opin Drug Deliv 5(9):1039–1046
Kearns VR, Williams RL (2009) Drug delivery systems for the eye. Expert Rev Med Devices
6(3):277–290
Kedhar SR, Jabs DA (2007) Cytomegalovirus retinitis in the era of highly active antiretroviral
therapy. Herpes 14:66–71
Kiernan DF, Mieler WF (2009) The use of intraocular corticosteroids. Expert Opin Pharmacother
10(15):2511–2525
Kimura H, Ogura Y (2001) Biodegradable polymers for ocular drug delivery. Ophthalmologica
215(3):143–155
Kulkarni RK, Pani KC, Neuman C, Leonard F (1966) Polylactic acid for surgical implants. Arch
Surg 93:839–843
Kuno N, Fujii S (2010 ) Biodegradable intraocular therapies for retinal disorders: progress to date.
Drugs Aging 27(2):117–134
Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup
SM, Dexamethasone DDS Phase II Study Group (2007) Randomized controlled study of an
intravitreous dexamethasone drug delivery system in patients with persistent macular edema.
Arch Ophthalmol 125:309–317
Kwak HW, D’Amico DJ (1992) Evaluation of the retinal toxicity and pharmacokinetics of dexam-
ethasone after intravitreal injection. Arch Ophthalmol 110:259–266
Lacrisert [prescribing information] (2007) Aton Pharma, Lawrenceville
Lee SY, Chee SP (2005) Surodex after phacoemulsification. J Cataract Refract Surg 31(8):1479–1480

228
S.S. Lee et al.
https://t.me/med1917
Lee SS, Yuan P, Robinson MR (2008) Ocular implants for drug delivery. In: Wnek GE, Bowlin GL
(eds) Encyclopedia of biomaterials and biomedical engineering. Informa Healthcare USA,
New York, pp 2259–2269
Lim JI, Wieland MR, Fung A, Hung DY, Wong V (2009) A phase 1 study evaluating the safety and
evidence of efficacy of IBI-20089, a triamcinolone intravitreal injection formulated with the
VerisomeTM drug delivery technology, in patients with cystoid macular edema. Invest
Ophthalmol Vis Sci 50:E-Abstract 5395
Macoul KL, Pavan-Langston D (1975) Pilocarpine Ocusert system for sustained control of ocular
hypertension. Arch Ophthalmol 93:587–590
Mansoor S, Kuppermann BD, Kenney MC (2009) Intraocular sustained-release delivery systems
for triamcinolone acetonide. Pharm Res 26(4):770–784
Miyamoto H, Ogura Y, Hashizoe M, Kunou N, Honda Y, Ikada Y (1997) Biodegradable scleral
implant for intravitreal controlled release of fluconazole. Curr Eye Res 16(9):930–935
Mohammad DA, Sweet BV, Elner SG (2007) Retisert: is the new advance in treatment of uveitis a
good one? Ann Pharmacother 41(3):449–454
Moritera T, Ogura Y, Honda Y, Wada R, Hyon SH, Ikada Y (1991) Microspheres of biodegradable
polymers as a drug-delivery system in the vitreous. Invest Ophthalmol Vis Sci 32:1785–1790
Moritera T, Ogura Y, Yoshimura N, Honda Y, Wada R, Hyon SH, Ikada Y (1992) Biodegradable
microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. Invest
Ophthalmol Vis Sci 33:3125–3130
Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi tm (2008) Nano/micro technologies
for delivering macromolecular therapeutics using poly(D, L-lactide-co-glycolide) and its deriv-
atives. J Control Release 125(3):193–209
Myles ME, Neumann DM, Hill JM (2005) Recent progress in ocular drug delivery for posterior seg-
ment disease: emphasis on transscleral iontophoresis. Adv Drug Deliv Rev 57(14):2063–2079
Navarro M, Michiardi A, Castaño O, Planell JA (2008) Biomaterials in orthopaedics. J R Soc
Interface 5(27):1137–1158
Ng TF, Lavik E, Keino H, Taylor AW, Langer RS, Young MJ (2007) Creating an immune-privileged site
using retinal progenitor cells and biodegradable polymers. Stem Cells 25(6):1552–1559
Ni Z, Hui P (2009) Emerging pharmacologic therapies for wet age-related macular degeneration.
Ophthalmologica 223(6):401–410
Nutropin Depot [prescribing information] (2005) Genetech, South San Francsico
Okabe J, Kimura H, Kunou N, Okabe K, Kato A, Ogura Y (2003) Biodegradable intrascleral
implant for sustained intraocular delivery of betamethasone phosphate. Invest Ophthalmol Vis
Sci 44(2):740–744
Park J, Lakes RS (2007) Biomaterials: an introduction, 3rd edn. Springer, New York
Park JH, Ye M, Park K (2005) Biodegradable polymers for microencapsulation of drugs. Molecules
10(1):146–161
Pieramici DJ, Rabena M, Castellarin AA, Nasir M, See R, Norton T, Sanchez A, Risard S, Avery
RL (2008) Ranibizumab for the treatment of macular edema associated with perfused central
retinal vein occlusions. Ophthalmology 115:e47–e54
Polak MB, Valamanesh F, Felt O, Torriglia A, Jeanny JC, Bourges JL, Rat P, Thomas-Doyle A,
BenEzra D, Gurny R, Behar-Cohen F (2008) Controlled delivery of 5-chlorouracil using
poly(ortho esters) in filtering surgery for glaucoma. Invest Ophthalmol Vis Sci 49(7):2993–3003
Quigley HA, Pollack IP, Harbin TS Jr (1975) Pilocarpine Ocuserts: long-term clinical trials and
selected pharmacodynamics. Arch Ophthalmol 93:771–775
Resnikoff S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP (2004)
Global data on visual impairment in the year 2002. Bull World Health Organ 82:844–851
Rogacka R, Chieffo A, Latib A, Colombo A (2008) Bioabsorbable and biocompatible stents. Is a
new revolution coming? Minerva Cardioangiol 56(5):483–491
Rokkanen P, Bostman O, Vianionpaaa S, Vihtonen K, Tormala P, Laiho J, Kilpikari J, Tamminmaki
M (1985) Biodegradable implants in fracture fixation: early results of treatment of fractures of
the ankle. Lancet 1:1422–1424

229
9 Advances in Biodegradable Ocular Drug Delivery Systems
https://t.me/med1917
Rönkkö S, Rekonen P, Sihvola R, Kaarniranta K, Puustjärvi T, Teräsvirta M, Uusitalo H (2009)
Histopathology of the three implanted degradable biopolymers in rabbit eye. J Biomed Mater
Res A 88(3):717–724
Rosenfeld PJ, Rich RM, Lalwani GA (2006) Ranibizumab: phase III clinical trial results.
Ophthalmol Clin North Am 19(3):361–372
Rosensaft PL, Webb RI (1981) Synthetic polyester surgical articles. US Patent 4,243,775
Rubsamen PE, Davis PA, Hernandez E, O’Grady GE, Cousins SW (1994) Prevention of experi-
mental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sus-
tained release of fluorouracil. Arch Ophthalmol 112(3):407–413
Sakhuja R, Mauri L (2010) Controversies in the use of drug-eluting stents for acute myocardial
infarction: a critical appraisal of the data. Annu Rev Med 61:215–231
Sakurai E, Matsuda Y, Ozeki H, Kunou N, Nakajima K, Ogura Y (2001) Scleral plug of biodegrad-
able polymers containing ganciclovir for experimental cytomegalovirus retinitis. Invest
Ophthalmol Vis Sci 42(9):2043–2048
Sakurai E, Nozaki M, Okabe K, Kunou N, Kimura H, Ogura Y (2003) Scleral plug of biodegrad-
able polymers containing tacrolimus (FK506) for experimental uveitis. Invest Ophthalmol Vis
Sci 44(11):4845–4852
Schultz CL, Poling TR, Mint JO (2009) A medical device/drug delivery system for treatment of
glaucoma. Clin Exp Optom 92(4):343–348
Seah SK, Husain R, Gazzard G, Lim MC, Hoh ST, Oen FT, Aung T (2005) Use of surodex in
phacotrabeculectomy surgery. Am J Ophthalmol 139(5):927–928
Shi W, Liu T, Xie L, Wang S (2005) FK506 in a biodegradable glycolide-co-clatide-co-caprolac-
tone polymer for prolongation of corneal allograft survival. Curr Eye Res 30(11):969–976
Shin JP, Park YC, Oh JH, Lee JW, Kim YM, Lim JO, Kim SY (2009) Biodegradable intrascleral
implant of triamcinolone acetonide in experimental uveitis. J Ocul Pharmacol Ther 25(3):201–208
Shive MS, Anderson JM (1997) Biodegradation and biocompatibility of PLA and PLGA micro-
spheres. Adv Drug Deliv Rev 28(1):5–24
Silva-Cunha A, Fialho SL, Naud MC, Behar-Cohen F (2009) Poly-epsilon-caprolactone intravitre-
ous devices: an in
Silverman BL, Blethen SL, Reiter EO, Attie KM, Neuwirth RB, Ford KM (2002) A long-acting
human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment
in children with growth hormone deficiency. J Pediatr Endocrinol Metab 15(suppl 2):715–722
Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, Freund KB, Klein R
(2009) Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity
secondary to central retinal vein occlusion. Am J Ophthalmol 147:298–306
Tan DT, Chee SP, Lim L, Lim AS (1999) Randomized clinical trial of a new dexamethasone deliv-
ery system (Surodex) for treatment of post-cataract surgery inflammation. Ophthalmology
106(2):223–231
Tan DT, Chee SP, Lim L, Theng J, Van Ede M (2001) Randomized clinical trial of Surodex steroid
drug delivery system for cataract surgery: anterior versus posterior placement of two Surodex
in the eye. Ophthalmology 108:2172–2181
Tanito M, Li F, Elliott MH, Dittmar M, Anderson RE (2007) Protective effect of TEMPOL
derivatives against light-induced retinal damage in rats. Invest Ophthalmol Vis Sci 48(4):
1900–1905
Tao W, Wen R, Laties A, Aguirre GD (2006) Cell-based delivery systems: development of encap-
sulated cell technology for ophthalmic applications. In: Ashton P, Jaffe GJ (eds) Intraocular
drug delivery. Taylor & Francis, New York, pp 111–128
Thanos CG, Bell WJ, O’Rourke P, Kauper K, Sherman S, Stabila P, Tao W (2004) Sustained secre-
tion of ciliary neurotrophic factor to the vitreous, using the encapsulated cell therapy-based
NT-501 intraocular device. Tissue Eng 10(11–12):1617–1622
Theng JT, Ti SE, Zhou L, Lam KW, Chee SP, Tan D (2003) Pharmacokinetic and toxicity study of
an intraocular cyclosporine DDS in the anterior segment of rabbit eyes. Invest Ophthalmol Vis
Sci 44(11):4895–4899
vivo study. Invest Ophthalmol Vis Sci 50(5):2312–2318

230 S.S. Lee et al.
https://t.me/med1917
Tomita M, Lavik E, Klassen H, Zahir T, Langer R, Young MJ (2005) Biodegradable polymer com-
posite grafts promote the survival and differentiation of retinal progenitor cells. Stem Cells
23(10):1579–1588
Törmälä P, Pohjonen T, Rokkanen P (1998) Bioabsorbable polymers: materials technology and
surgical applications. Proc Inst Mech Eng H 212(2):101–111
Uppal P, Jampel HD, Quigley HA, Leong KW (1994) Pharmacokinetics of etoposide delivery by
a bioerodible drug carrier implanted at glaucoma surgery. J Ocul Pharmacol 10(2):471–479
Wada R, Hyon SH, Ikada Y (1992) Injectable microspheres with controlled drug release for glau-
coma filtering surgery. Invest Ophthalmol Vis Sci 33:3436–3441
Wadhwa S, Paliwal R, Paliwal SR, Vyas SP (2009) Nanocarriers in ocular drug delivery: an update
review. Curr Pharm Des 15(23):2724–2750
Wassermann D, Versfelt CC (1974) Use of stannous octoate catalyst in the manufacture of L(−)
lactide-glycolide copolymer sutures. US Patent 3,839,297
Wei X, Gong C, Gou M, Fu S, Guo Q, Shi S, Luo F, Guo G, Qiu L, Qian Z (2009) Biodegradable
poly(epsilon-caprolactone)-poly(ethylene glycol) copolymers as drug delivery system. Int J
Pharm 381(1):1–18
Williams GA, Haller JA, Kuppermann BD, Dexamethasone DDS Phase II Study Group (2009)
Dexamethasone posterior-segment drug delivery system in the treatment of macular edema
resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 147(6):1048–1054
Xinming L, Yingde C, Lloyd AW, Mikhalovsky SV, Sandeman SR, Howel CA, Liewen L (2007)
Polymeric hydrogels for novel contact lens-based ophthalmic drug delivery systems: a review.
Cant Lens Anterior Eye 31(2):57–64
Xu X, Liu T, Liu S, Zhang K, Shen Z, Li Y, Jing X (2009) Feasibility of biodegradable PLGA
common bile duct stents: an in
20(5):1167–1173
Yasukawa T, Kimura H, Kunou N, Miyamoto H, Honda Y, Ogura Y, Ikada Y (2000) Biodegradable
ganciclovir-PLA scleral implant for intravitreal drug delivery in cytomegalovirus retinitis.
Graefes Arch Clin Exp Ophthalmol 238(2):186–190
Yasukawa T, Kimura H, Tabata Y, Miyamoto H, Honda Y, Ogura Y (2002) Sustained release of
cis-hydroxyproline in the treatment of experimental proliferative vitreoretinopathy in rabbits.
Graefes Arch Clin Exp Ophthalmol 240(8):672–678
Yasukawa T, Ogura Y, Kimura H, Sakurai E, Tabata Y (2006) Drug delivery from ocular implants.
Expert Opin Drug Deliv 3(2):261–273
vitro and in vivo study. J Mater Sci Mater Med
Соседние файлы в папке Библиотека им академика М.И. Перельмана
